Results 81 to 90 of about 45,696 (262)

OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs

mSphere, 2019
Infections due to carbapenemase-producing Gram-negative pathogens are associated with limited treatment options and consequently lead to increased mortality and morbidity.
Christopher Fröhlich, Vidar Sørum, Ane Molden Thomassen, Pål Jarle Johnsen, Hanna-Kirsti S. Leiros, Ørjan Samuelsen   +5 more
doaj   +1 more source

German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant Pseudomonas aeruginosa Isolates Using a Commercially Available Broth Microdilution Assay

Antibiotics, 2022
Multidrug resistance is an emerging healthcare issue, especially concerning Pseudomonas aeruginosa. In this multicenter study, P. aeruginosa isolates with resistance against meropenem detected by routine methods were collected and tested for ...
Jana Manzke, Raphael Stauf, Bernd Neumann, Ernst Molitor, Gunnar Hischebeth, Michaela Simon, Jonathan Jantsch, Jürgen Rödel, Sören L. Becker, Alexander Halfmann, Thomas A. Wichelhaus, Michael Hogardt, Annerose Serr, Christina Hess, Andreas F. Wendel, Ekkehard Siegel, Holger Rohde, Stefan Zimmermann, Jörg Steinmann   +18 more
doaj   +1 more source

In vitro antibacterial activity of ceftazidime/avibactam in combination against planktonic and biofilm carbapenemase-producing Klebsiella pneumoniae isolated from blood

Journal of Global Antimicrobial Resistance, 2020
Objectives: The aim of this study was to report on in vitro tests of antibacterial activity of ceftazidime/avibactam in combination against planktonic or biofilm KPC carbapenemase-producing Klebsiella pneumoniae (KPC-Kp), the rate of KPC-Kp blood ...
Chiara Papalini, Samuele Sabbatini, Claudia Monari, Antonella Mencacci, Daniela Francisci, Stefano Perito, Maria Bruna Pasticci   +6 more
doaj   +1 more source

Emergence of Fosfomycin Resistance Among ESBL‐Producing Escherichia coli in Abadan, Southwestern Iran

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aim Escherichia coli is a key pathogen responsible for various infections, such as urinary tract infections, gastroenteritis, and wound infections. The increasing occurrence of antimicrobial resistance, particularly in extended‐spectrum β‐lactamase (ESBL)‐producing strains, poses a significant global health threat.
Nabi Jomehzadeh, Ali Fakari
wiley   +1 more source

The Role of Pharmacovigilance Database in Identifying Antibiotic Resistance and Inappropriate Use: An Analysis of VigiBase Reports From Lower‐Middle‐Income Countries

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Background Digital databases such as pharmacovigilance (PV) databases could provide unique opportunities to monitor trends in suspected antibiotic resistance, ineffectiveness, and misuse, extending beyond their traditional role of tracking adverse drug reactions (ADRs).
Hager Saleh, Joseph Mitchell, Cecilia Stålsby Lundborg, Megha Sharma   +3 more
wiley   +1 more source

Rates of resistance to ceftazidime-avibactam and ceftolozane-tazobactam among patients treated for multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia.

Clinical Infectious Diseases
Among consecutive patients with multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia we found those treated with ceftazidime-avibactam were more likely to develop resistance (defined as ≥4-fold increased MIC) than those treated with ...
Sunish Shah, Ellen G. Kline, G. Haidar, Kevin M. Squires, J. Pogue, E. McCreary, Justin Ludwig, L. Clarke, Madison E. Stellfox, D. Van Tyne, R. K. Shields   +10 more
semanticscholar   +1 more source

Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination

, 2013
Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes. This review summarizes the existing data published for ceftazidime-
Hoban, Daryl J., Zhanel, George G., Karlowsky, James A., Adam, Heather, Lawson, Christopher D., Schweizer, Frank, Gin, Alfred S., Lynch, Joseph P., Zelenitsky, Sheryl, Denisuik, Andrew, Rubinstein, Ethan, Lagacé-Wiens, Philippe R. S.   +11 more
core   +1 more source

Guidelines for Essential Trauma Care: Second Edition (2026)

World Journal of Surgery, Volume 50, Issue 6, Page 1409-1450, June 2026.
Injury is a major cause of death and disability globally, with the highest burden in low‐ and middle‐income countries (LMICs). Strengthening the organization and planning for trauma care (care of the injured) can improve care and lower mortality. In 2004, the International Association for Trauma Surgery and Intensive Care (IATSIC) and the World Health ...
Charles Mock, Timothy C. Hardcastle, Christine Gaarder, Amit Gupta, Adam Gyedu, Manjul Joshipura, Elmin Steyn, on behalf of the Essential Trauma Care revision author group, Valencia Adjei, Roger Alcock, Vanda Amado, Michael Boampong, Sanjeev Booi, Petra Brysiewicz, Corazon Cabanilla‐Manuntag, Cristiane de Alencar Domingues, Ghada Elhadari, Ranjith Nanda Ellawala, Sarnai Erdene, Ama Akoma Essuman, Jorge Esteban Foianini, Filippo Gatti, Armando Garcia Guererra, Greg Hynes, Adil Haider, Sandy Ingless, Balavenkata Jagannathan, Helen Jowett, Knut Magne Kolstadbråten, Sonja Krofak, Aireen Patricia Madrid, Tina Tomić Mahečić, Claude Martin, Daniel Ntogwrachu, Bisola Onajin‐Obembe, Nhobojit Roy, Andres Rubiano, Niisoja Mensah Torto, Ben Wachira, Meg Walmsley, Torben Wisborg, Elma Wong   +41 more
wiley   +1 more source

Zwitterionic Penicillin‐Derived Sulfone Inhibitor for Combating β‐Lactamase‐Mediated Antibiotic Resistance

ChemMedChem, Volume 21, Issue 9, 14 May 2026.
Combining enhanced permeability strategies with (2‐pyridyl)methylene substitution in the sulbactam scaffold led to a novel β‐lactamase inhibitor to combat β‐lactamase‐mediated resistance to β‐lactam antibiotics. The studies presented highlight the potential of compound 3 as a next‐generation β‐lactamase inhibitor for combating infections caused by ...
Diana Rodríguez, Emilio Lence, Juan C. Vázquez‐Ucha, Alejandro Beceiro, Concepción González‐Bello   +4 more
wiley   +1 more source

Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum β-lactamases

Antimicrobial Agents and Chemotherapy
The impact of penicillin-binding protein 3 (PBP3) modifications that may be identified in Escherichia coli was evaluated with respect to susceptibility to β-lactam/β-lactamase inhibitor combinations including ceftazidime-avibactam, imipenem-relebactam ...
C. Le Terrier, P. Nordmann, Chloé Buchs, L. Poirel   +3 more
semanticscholar   +1 more source